Piramal Pharma has informed the stock exchanges that the United States Food and Drug Administration (FDA) has issued an Establishment Inspection Report (EIR) for the company’s manufacturing facility located at Digwal, Telangana, India. The issuance of the EIR indicates that the inspection has been successfully closed by the FDA.

The company stated that the disclosure was made in continuation of its earlier communication dated February 14, 2026, regarding the FDA inspection conducted at the Digwal manufacturing site.

It further noted that the intimation regarding receipt of the EIR was submitted on the first working day following receipt of the report from the regulator.